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Abstract
Background: Previous studies have suggested that antibodies against human leukocyte antigen (HLA) are
associated with worse outcomes in lung transplantation. However, little is known about the factors associated with
outcomes following lung transplantation in Asia. Accordingly, we investigated the prevalence of anti-HLA
antibodies in recipients before transplantation and assessed their impact on outcomes in Korea.
Methods: A single-center retrospective study was conducted. The study included 76 patients who received a lung
transplant at a tertiary hospital in South Korea between January 2010 and March 2015.
Results: Nine patients (11.8%) had class I and/or class II panel-reactive antibodies greater than 50%. Twelve patients
(15.8%) had anti-HLA antibodies with a low mean fluorescence intensity (MFI, 1000–3000), 7 (9.2%) with a moderate
MFI (3000–5000), and 12 (15.8%) with a high MFI (> 5000). Ten patients (13.2%) had suspected donor-specific
antibodies (DSA), and 60% (6/10) of these patients had antibodies with a high MFI. In an analysis of outcomes,
high-grade (≥2) primary graft dysfunction (PGD) was more frequent in patients with anti-HLA antibodies with
moderate-to-high MFI values than in patients with low MFI values (39.4% vs. 14.0%, p = 0.011). Of 20 patients who
survived longer than 2 years and evaluated for pBOS after transplant, potential bronchiolitis obliterans syndrome
(pBOS) or BOS was more frequent in patients with anti-HLA antibodies with moderate-to-high MFI than in patients
with low MFI, although this difference was not statistically significant (50.0% vs. 14.3%, p = 0.131).
Conclusions: The prevalence of anti-HLA antibodies with high MFI was not high in Korea. However, the MFI was
relatively high in patients with DSA. Anti-HLA antibodies with moderate-to-high MFI values were related to high-
grade PGD. Therefore, recipients with high MFI before lung transplantation should be considered for desensitization
and close monitoring.
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Background
Lung transplantation is the ultimate therapeutic option
for patients with end-stage lung disease. Despite im-
provements in transplantation techniques and immuno-
suppression therapy, the current 5-year survival rate is
only 57% [1]. The presence of antibodies against human
leukocyte antigens (HLA) prior to transplantation is
reported to be associated with worse post-transplant
outcomes [2–6]. However, evidence for this association
in lung transplantation is not as strong as that for other
types of solid organ transplantation.
Elevated panel-reactive antibody (PRA) levels before
lung transplant are linked to adverse graft outcomes and
post-transplant survival. Several studies have found that
lung transplant recipients with elevated pre-transplant
PRA tend to exhibit more ventilator days after transplant,
development of bronchiolitis obliterans syndrome, and a
low graft survival rate [7–14]. However, there is no con-
sensus about the cutoff PRA level or the appropriate mean
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fluorescence intensity (MFI) threshold for identifying anti-
HLA antibodies or assessing their impact on outcomes in
lung transplant recipients. A recent study has reported an
association between pre-transplant anti-HLA antibodies
with high MFI values (i.e., > 3000) and a high rate of
antibody-mediated rejection [15].
Limited data exist regarding the distribution and im-
pact of anti-HLA antibodies before lung transplantation
in Asia, despite the increasing number of lung transplan-
tations in the region, indicating the importance of these
analyses. The objectives of this study were (1) to investi-
gate the prevalence of pre-transplant anti-HLA anti-
bodies for a wide spectrum of thresholds in patients
prior to lung transplant and (2) to assess their impact on
outcomes in lung transplant recipients in Korea.
Methods
Study design and population
In this retrospective study, the medical records of con-
secutive lung transplant recipients at one tertiary care
hospital in South Korea between January 2010 and
March 2015 were reviewed. Pediatric cases (< 16 years of
age) and heart-lung transplantation cases were excluded.
In total, 76 lung transplant recipients, who were
followed through September 2015, were included.
Immunologic evaluation
Before transplantation, all patients underwent panel re-
active antibody (PRA) class I and class II identification
(Immucor, Stamford, CT, USA). The anti-HLA anti-
bodies specificity is classified into 1000, 3000, and
10,000 based on the MFI value. MFI < 1000 is very weak,
1000 ≤MFI < 3000 is weak, 3000 ≤MFI < 10,000 is mod-
erate, and above 10,000 is strong. The cut off value of
MFI considered to be anti HLA Ab positive is 1000. The
highest mean fluorescence intensity (MFI) was recorded
as the MFI. Anti-HLA antibodies against donor HLA
was defined as donor-specific antibodies (DSA). DSA
was quantified based on MFI, the cutoff value of MFI
considered as DSA positive is 500.
Clinical settings
The transplantation was performed regardless of the sta-
tus of DSA because of the problem of donor shortage.
And we considered desensitization protocol including
plasma exchange and immunoglobulin after lung trans-
plantation in patients with pre-transplant DSA and
MFI ≥ 3000.
All patients received induction therapy with high-dose
steroids (methylprednisolone, 500 mg), followed by
standard triple immunosuppressive therapy consisting of
tacrolimus, mycophenolate, and prednisolone after lung
transplant. Pre-transplant immunological results did not
affect the choice of immunosuppressant regimen.
Clinical outcomes
Clinical outcomes included primary graft dysfunction
(PGD) and bronchiolitis obliterans syndrome (BOS). PGD
after lung transplantation represents an injury to the
transplanted lung that develops in the first 72 h after
transplantation. The severity of PGD is graded based on
the ratio of arterial oxygen pressure to the inspired oxygen
concentration (PaO2/FiO2) and the presence of infiltration
on chest radiographs according to the International Soci-
ety for Heart and Lung Transplantation (ISHLT) criteria
[16]. BOS was identified as a progressive decline in forced
expiratory volume in 1 s (FEV1) after excluding other eti-
ologies. BOS was diagnosed according to the criteria of
ISHLT. A potential BOS (pBOS) stage defined by a 10% to
19% decrease in FEV1 and/or by a ≥ 25% decrease in
FEF25–75 from baseline [17, 18]. The incidence of BOS
could not be determined because the study period was
relatively short; accordingly, pBOS was used as an out-
come, instead of BOS. pBOS was analyzed in patients who
survived longer than 2 years after lung transplantation.
Statistical analysis
All analyses were performed using SPSS (version 20.0)
(SPSS, Inc., Chicago, IL, USA). Continuous variables are
reported as means and standard deviations, and categor-
ical variables are reported as counts and percentages.
Recipient characteristics in groups distinguished by anti-
HLA antibodies were compared using Fisher’s exact tests
and Mann–Whitney U tests for categorical and continu-
ous variables, respectively. A two-tailed p-value of < 0.05
was considered statistically significant.
Ethics
Informed consent was waived because this was a retro-
spective study. The research protocol was approved by
the Institutional Review Board (IRB) of Severance
Hospital (IRB No. 4–2013-0770).
Results
In total, 76 lung transplant recipients were included in
the analysis. Patients were followed from the time of
lung transplantation until death or the end of the study
period.
Baseline characteristics
Table 1 summarizes the baseline characteristics of re-
cipients. The median patient age was 52.0 years
(range, 17–75 years) and 42 recipients (55.3%) were
male. Primary diagnosis consisted of 37 cases of idio-
pathic pulmonary fibrosis (48.7%), 4 cases of chronic
obstructive lung disease (COPD) (5.3%), 1 of pulmonary
artery hypertension (1.3%), 4 of destroyed lung by tuber-
culosis (5.3%), 5 of interstitial lung disease with connective
tissue disease (6.6%), 9 of lymphangioleiomyomatosis
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(11.8%), 3 of idiopathic interstitial pneumonia other than
idiopathic pulmonary fibrosis (IPF) (3.9%), 11 of bronchio-
litis obliterans after stem cell transplantation (14.5%), and
2 cases of others diseases, such as diffuse panbronchiolitis
and Langerhans cell histiocytosis (2.6%). The most com-
mon transplantation type was a bilateral lung transplant-
ation (62 patients, 81.6%).
When divided into two groups based on a class I/II
PRA value of < 50% and ≥50%, the only factor that dif-
fered significantly between groups was age; patients in
the PRA ≥50% group were younger than those in the
PRA < 50% group (53 vs. 44 years, p = 0.013). Patient
subgroups dichotomized according to PRA levels were
similar with respect to recipient characteristics, except
age (Table 1).
Prevalence of anti-HLA antibodies
Among 76 patients, high levels of class I or class II PRA
(≥50%) were detected in 9 patients (11.8%). In terms of
the distribution of MFI, 12 patients (15.8%) had anti-
HLA antibodies with a low MFI (1000–3000), 7 (9.2%)
had a moderate MFI (3000–5000), and 12 (15.8%) had a
high MFI (> 5000). The proportion of patients with a
high PRA and the distribution of MFI were relatively
similar between Class I and Class II (Table 2).
At the time of lung transplantation, all recipients
were screened for DSA based on the presence of anti-
bodies to HLA of the respective donor, as determined
by PRA. Ten patients (13.2%) had DSA. Most of the
10 DSA-positive recipients (7/10, 70%) had high PRA
and 60% (6/10) had high MFI (> 5000) anti-HLA anti-
bodies. In contrast, only 3% of patients without DSA
had high PRA, and 9.1% of patients without DSA (6/
66) had high MFI. However, there were no differences
in non-immunological factors, such as age, sex, BMI,
underlying disease, and surgery type of lung trans-
plantation, between patients with and without DSA
(Table 3).
Table 1 Recipients characteristics of patients with class I/II panel reactive antibody < 50% and ≥50%
All recipients (n = 76) PRA < 50% (n = 67) PRA≥ 50% (n = 9) p-value
Age, median (range), yrs 52.0 (17–75) 53.0 (18–75) 44.0 (17–52) 0.013
Male, n (%) 42 (55.3) 39 (58.2) 3 (33.3) 0.284
BMI, median (IQR), kg/m2 19.1 (17.4–21.6) 19.0 (17.4–21.6) 19.8 (16.1–21.6) 0.981
ABO, n (%) 0.413
A 26 (34.2) 24 (35.8) 2 (22.2)
B 26 (34.2) 23 (34.3) 3 (33.3)
AB 6 (7.9) 4 (6.0) 2 (22.2)
O 18 (23.7) 16 (23.9) 2 (22.2)
Primary diagnosis, n (%) 0.277
COPD/emphysema 4 (5.3) 3 (4.5) 1 (11.1)
IPF 37 (48.7) 35 (52.2) 2 (22.2)
IPAH 1 (1.3) 1 (1.5) 0 (0)
IIP other than IPF* 3 (3.9) 2 (3.0) 1 (11.1)
Bronchiectasis/ destroyed lung by TB 4 (5.3) 4 (6.0) 0 (0)
BOS after HSCT 11 (14.5) 9 (14.9) 2 (22.2)
Interstitial lung disease related with CTD 5 (6.6) 4 (6.0) 1 (11.1)
LAM 9 (11.8) 7 (10.4) 2 (22.2)
Others** 2 (2.6) 2 (3.0) 0 (0)
Smoking, n (%) 0.141
Smoker 30 (39.5) 29 (43.3) 1 (11.1)
≥ 20 pack-years 22 (28.9) 21 (31.3) 1 (11.1)
< 20 pack-years 8 (10.6) 8 (12.0) 0 (0)
Never smoker 46 (60.5) 38 (56.7) 8 (88.9)
Bilateral lung transplantation, n (%) 62 (81.6) 53 (79.1) 9 (100) 0.197
*NSIP and AIP were included
**Others: diffuse panbronchiolitis, langerhans cell histiocytosis
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; IPAH, Idiopathic pulmonary arterial hypertension; IIP,
Idiopathic interstitial pneumonia; TB, tuberculosis; BOS, Bronchiolitis obliterans syndrome; CTD, connective tissue disease; LAM, Lymphangioleiomyomatosis; NSIP,
non-specific interstitial pneumonia; AIP, acute interstitial pneumonia; HSCT, hematopoietic stem cell transplantation
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Outcomes
According to the grade of PGD, patients were divided
into 2 groups, i.e., non-high-grade PGD (grade 0–1) and
high-grade PGD (grade ≥ 2). High-grade PGD developed
in 33 patients (43.3%). High-grade PGD developed in
more patients with anti-HLA antibodies of moderate or
high MFI values (≥3000) than in patients with low MFI
values (39.4% vs. 14.0%, p = 0.011). High PRA titers or
the presence of DSA was not associated with the devel-
opment of high-grade PGD (Table 4).
Table 5 shows the association between pre-
transplanted anti-HLA antibodies and pBOS or BOS.
Twenty patients who survived longer than 2 years after
transplantation and underwent pulmonary function test
for BOS evaluation were evaluated, and pBOS or BOS
developed in 6 of these patients (30%) among 20 pa-
tients. Four (20%) patients had pBOS and 2 (10%) pa-
tients had BOS. pBOS or BOS was more frequent in
patients with anti-HLA antibodies of moderate or high
MFI (≥3000) than in patients with low MFI (< 3000), al-
though this difference was not statistically significant
(50.0% vs. 14.3%, p = 0.131). Additionally, the associa-
tions between high PRA and pBOS or BOS and the asso-
ciations between the presence of DSA and pBOS or BOS
were not significant, respectively. Non-immune initiated
factors such as cytomegalovirus (CMV) infection,
Pseudomonas airway colonization, and airway ischemia,
which may affect rejection after transplantation [19–21]
were also evaluated, however, there was no difference
between two groups.
Discussion
In this study, we performed a detailed immunological as-
sessment of a cohort of patients who underwent lung
transplantation and revealed the relationship between
the degree of pre-transplant sensitization and post-
transplant clinical outcomes.
We investigated sensitization before lung transplant-
ation, as defined either by (i) high PRA and/or high MFI
antibodies against class I and/or class II HLA or (ii) the
presence of HLA class I and/or class II DSA. The pro-
portion of patients with high PRA (> 50%) (class I, 7.9%;
class II, 5.3%; total 11.8%) and high MFI (≥5000) (class I,
13.2%; class II, 3.9%; total 15.8%) were not high in Korea.
DSA was observed in 13.2% of patients and was corre-
lated with a high PRA or high MFI.
The presence of HLA antibodies differs among studies.
In a retrospective study by Hadjiliadis et al., 101 of 656
lung transplantation recipients (15.4%) showed a PRA
greater than 0 before transplantation, 37 (5.6%) patients
had a PRA greater than 10%, and 20 (3.0%) patients had
a PRA greater than 25% using cell-based complement
dependent cytotoxicity (CDC) techniques [7]. As an-
other solid organ, Gebel et al. reported that 25%–50% of
patients on the waiting list for kidney transplantation
have a PRA level of higher than 20% based on both
CDC and flow cytometry [22]. In an analysis of heart
transplantation, Tambur et al. reported that 5.5% of re-
cipients had high PRA levels (PRA > 10%) before trans-
plant by CDC. However, 72 patients (32.9%) had pre-
transplant anti-HLA antibodies detectable by a flow cy-
tometric approach to PRA testing (class I, 34 patients;
class II, 7 patients; class I and II, 31 patients) [2]. Histor-
ically, anti-HLA antibodies were detected using the
complement-dependent cytotoxicity (CDC) assays. This
technique is complemented by solid phase assays using
Luminex apparatus. Luminex assay is more sensitive
Table 2 Prevalence of pre-transplant panel reactive antibody
and donor-specific antibodies
Recipients (n = 76)
Total
cPRA
Not detected 41 (54.0)
PRA < 50% 26 (34.2)
PRA≥ 50% 9 (11.8)
Anti-HLA Ab (MFI)
< 1000 45 (59.2)
1000≤MFI < 3000 12 (15.8)
3000≤MFI < 5000 7 (9.2)
≥ 5000 12 (15.8)
Class I
cPRA
Not detected 50 (65.8)
Class I PRA < 50% 20 (26.3)
Class I PRA≥ 50% 6 (7.9)
Anti-HLA Ab (MFI)
< 1000 54 (71.1)
1000≤MFI < 3000 11 (14.5)
3000≤MFI < 5000 2 (2.6)
≥ 5000 10 (13.2)
Class II
cPRA
Not detected 54 (71.0)
Class I PRA < 50% 18 (23.7)
Class I PRA≥ 50% 4 (5.3)
Anti-HLA Ab (MFI)
< 1000 59 (77.6)
1000≤MFI < 3000 9 (11.8)
3000≤MFI < 5000 6 (7.9)
≥ 5000 3 (3.9)
cPRA, calculated panel reactive antibody; PRA, panel reactive antibody; HLA,
human leukocyte antigen; MFI, mean fluorescence intensity
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than the conventional CDC method [23–25]. A recent
report by Goldberg et al. on the basis of results using
Luminex assays showed that 30% of subjects had cir-
culating class I HLA antibodies alone, 4% Class II,
and 14.4% class I and class II at MFI > 1000 [26]. Ac-
cording to Chung et al., of 129 patients who were
waiting for a kidney transplant in Korea, 56 patients
(43.4%) had PRA ≥ 20% by solid phase Luminex PRA,
45 patients (34.9%) had anti-HLA antibodies based on
a Luminex single antigen assay, and 25 patients
(44.6%) had HLA-DSA [27]. Although the prevalence
of anti-HLA antibodies differed depending on the test
method, similar results were obtained when the same
test method was used, including this study. In our
analysis, the proportion of high PRA or anti-HLA Ab
titer is not high compared to previous studies.
The lower median age in the group with PRA ≥ 50%
may be explained by the young age of the two patients
with BOS after hematopoietic stem cell transplantation
(HSCT), i.e., 17 and 18 years old. There are no similar
Table 3 Recipients characteristics with or without Donor Specific Antibody
Donor Specific Antibody p-value
Yes (n = 10) No (n = 66)
Anti-HLA Ab (%) < 0.001
PRA≥ 50% 7 (70.0) 2 (3.0)
Anti-HLA Ab (MFI) < 0.001
< 1000 0 (0) 45 (68.2)
1000≤MFI < 3000 3 (30.0) 9 (13.6)
3000≤MFI < 5000 1 (10.0) 6 (9.1)
≥ 5000 6 (60.0) 6 (9.1)
Age, median (range), yrs 48.5 (17–57) 52.0 (17–75) 0.180
Male, n (%) 5 (50.0) 37 (56.1) 0.745
BMI, median (IQR), kg/m2 18.4 (14.3–20.0) 19.3 (17.5–22.2) 0.161
ABO, n (%) 0.708
A 2 (20.0) 24 (36.4)
B 4 (40.0) 22 (33.3)
AB 1 (10.0) 5 (7.6)
O 3 (30.0) 15 (22.7)
Primary diagnosis, n (%) 0.321
COPD/emphysema 2 (20.0) 2 (3.0)
IPF 3 (30.0) 34 (51.5)
IPAH 0 (0) 1 (1.5)
IIP other than IPF* 0 (0) 3 (4.5)
Bronchiectasis/destroyed lung by TB 0 (0) 4 (6.1)
BOS after HSCT 2 (20.0) 9 (13.6)
Interstitial lung disease related with CTD 1 (10.0) 4 (6.1)
LAM 2 (20.0) 7 (10.6)
Others** 0 (0) 2 (3.0)
Smoking, n (%) 0.733
Smoker 3 (30.0) 26 (39.4)
≥ 20 pack-years 3 (30.0) 19 (28.8)
< 20 pack-years 0 (0) 7 (10.6)
Never smoker 7 (70.0) 40 (60.6)
Bilateral lung transplantation, n (%) 9 (90.0) 53 (80.3) 0.678
*NSIP and AIP were included
**Others: diffuse panbronchiolitis, langerhans cell histiocytosis
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; IPAH, Idiopathic pulmonary arterial hypertension; IIP,
Idiopathic interstitial pneumonia; TB, tuberculosis; BOS, Bronchiolitis obliterans syndrome; CTD, connective tissue disease; LAM, Lymphangioleiomyomatosis; NSIP,
non-specific interstitial pneumonia; AIP, acute interstitial pneumonia; HSCT, hematopoietic stem cell transplantation
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reports; additionally, our results could be explained by
an impact of previous HSCT on PRA.
The distribution of DSA positivity differs among stud-
ies. Brugiere et al. reported that 14%, 20%, and 32% of
patients had class I, II, and I and II DSA, respectively, in
France and the proportion of patients with DSA was
somewhat higher than that in our study [28]. In contrast,
Song et al. reported that 32 (14.5%) recipients were posi-
tive for DSAs against donor HLAs by PRA among 219
living donor liver transplant recipients in Korea [29]. In
a study in which Rose et al. reported cardiac transplant-
ation, 53 (9.4%) of 565 patients had DSA detectable by
Luminex assays before transplant [30]. These discrepan-
cies among studies may be related to differences in race
or methodological differences. In our study, the DSA-
positive group showed significantly higher levels of class
I and II PRA than those of the DSA-negative group,
consistent with previous results. Eventually, patients
with high PRA (%) and high MFI values for anti-HLA
antibodies should be considered as having a high prob-
ability of DSA, regardless of donor.
Many studies have shown that high PRA before trans-
plantation increases the risk of mortality with acute and
chronic transplant rejection after solid organ transplant-
ation [7, 31, 32]. In particular, the presence of anti-HLA
antibodies promotes BOS, the predominant cause of
mortality in patients exhibiting long-term survival after
lung transplantation [33–35]. Lau et al. reported that
sensitized patients experience a significantly higher inci-
dence of bronchiolitis obliterans syndrome than that of
non-sensitized patients (56% vs. 23%, p = 0.044).
Additionally, 2-year survival decreased (58% vs. 73%, p =
0.31) and pathology suggesting antibody-mediated injury
in lung transplant recipients was related to an elevated
pre-transplant PRA [10]. Furthermore, Shah et al. re-
ported an increased mortality when total PRA levels
exceeded 25% [8].
Our analysis of the effect of anti-HLA antibodies on
post-transplant outcomes showed that high-grade PGD
was related to a high MFI. In a literature review, a direct
correlation between high anti-HLA antibodies and PGD
incidence has not been reported; however, the cause of
Table 4 Association of pre-transplant panel reactive antibody with primary graft dysfunction status
PGD 0–1 (n = 43) PGD 2–3 (n = 33) p-value
Total
cPRA > 0.999
Not detected or PRA < 50%, n (%) 38 (88.4) 29 (87.9)
PRA≥ 50%, n (%) 5 (11.6) 4 (12.1)
Anti-HLA Ab (MFI) 0.011
Not detected or MFI < 3000, n (%) 37 (86.0) 20 (60.6)
MFI≥ 3000, n (%) 6 (14.0) 13 (39.4)
Class I 0.394
cPRA
Not detected or PRA < 50%, n (%) 41 (95.3) 29 (87.9)
PRA≥ 50%, n (%) 2 (4.7) 4 (12.1)
Anti-HLA Ab (MFI) 0.077
Not detected or MFI < 3000, n (%) 39 (90.7) 25 (75.8)
MFI≥ 3000, n (%) 4 (9.3) 8 (24.2)
Class II
cPRA
Not detected or PRA < 50%, n (%) 40 (93.0) 32 (97.0) 0.628
PRA≥ 50%, n (%) 3 (7.0) 1 (3.0)
Anti-HLA Ab (MFI) 0.071
Not detected or MFI < 3000, n (%) 41 (95.3) 27 (81.8)
MFI≥ 3000, n (%) 2 (4.7) 6 (18.2)
Donor Specific Antibody 0.739
Yes, n (%) 5 (11.6) 5 (15.2)
No, n (%) 38 (88.4) 28 (84.8)
cPRA, calculated panel reactive antibody; PRA, panel reactive antibody; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; PGD, primary graft
dysfunction; CMV, cytomegalovirus; R, recipient; D, donor
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PGD is considered multifactorial and could include the in-
flammatory response associated with anti-HLA. Hadjilia-
dis et al. reported that an elevated pre-transplant PRA in
lung transplant recipients is associated with poor survival,
especially during the early post-transplant period; this was
attributed to a direct effect of anti-HLA antibodies on the
allograft [7]. Bharat et al. reported that PGD is associated
with an inflammatory cascade that augments the anti-
HLA response that predisposes patients to BOS. Based on
many previous studies as well as the results of this study,
an immunological response may be one of the mecha-
nisms among the multifactorial causes of PGD [26].
Similar results have been reported for other solid
organ transplant types. Perera et al. found that pre-
existing DSA may result in early morbidity in liver trans-
plant recipients. In a renal transplant study, Caro-Oleas
et al. reported that patients with existing or de novo
anti-HLA-DSA had the highest likelihood of rejection
episodes. In this study, patients with DSA-positive re-
sults were more likely to have a high MFI and therefore
had a high risk of acute rejection. Therefore, in patients
with a high MFI, the occurrence of PGD immediately
after lung transplantation should be closely monitored.
The majority of recipients with elevated PRA had risk
factors for humoral sensitization. In particular, humoral
immune responses after transplant are associated with
BOS development according to several studies, empha-
sizing the need for the monitoring of anti-HLA
Table 5 Association of pre-transplant panel reactive antibody with potential BOS
BOS 0 (n = 14) ≥pBOS (n = 6) p-value
Total
cPRA > 0.999
Not detected or PRA < 50%, n (%) 12 (85.7) 5 (83.3)
PRA≥ 50%, n (%) 2 (14.3) 1 (16.7)
Anti-HLA Ab (MFI) 0.131
Not detected or MFI < 3000, n (%) 12 (85.7) 3 (50)
MFI≥ 3000, n (%) 2 (14.3) 3 (50)
Class I
cPRA > 0.999
Not detected or PRA < 50%, n (%) 12 (85.7) 5 (83.3)
PRA≥ 50%, n (%) 2 (14.3) 1 (16.7)
Class I anti-HLA Ab (MFI) 0.549
Not detected or MFI < 3000, n (%) 12 (85.7) 4 (66.7)
MFI≥ 3000, n (%) 2 (14.3) 2 (33.3)
Class II
cPRA –
Not detected or PRA < 50%, n (%) 14 (100) 6 (100)
PRA≥ 50%, n (%) – –
Class II anti-HLA Ab (MFI) 0.079
Not detected or MFI < 3000, n (%) 14 (100) 4 (66.7)
MFI≥ 3000, n (%) 0 (0) 2 (33.3)
Donor Specific Antibody > 0.999
Yes, n (%) 2 (14.3) 1 (16.7)
No, n (%) 12 (85.7) 5 (83.3)
CMV status
Donor + / Recipient -, n (%) 0 (0) 0 (0) –
Donor + / Recipient +, n (%) 14 (100) 6 (100) –
Donor BAL culture +, n (%) 9 (64.3) 2 (33.3) 0.336
Pseudomonas aeruginosa colonization, n (%) 1 (7.1) 1 (16.7) 0.521
Ischemic time, min (mean ± SD) 213.2 ± 62.8 197.0 ± 55.6 0.386
cPRA, calculated panel reactive antibody; PRA, panel reactive antibody; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; BOS, bronchiolitis
obliterans syndrome; pBOS, potential bronchiolitis obliterans syndrome; CMV, cytomegalovirus; BAL, bronchoalveolar lavage
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antibodies prior to lung transplantation. Andres et al.
suggested that the development of anti-HLA antibodies
after lung transplant plays an important role in the de-
velopment of BOS [36]. However, based on our results,
we cannot definitively confirm the relationship between
high PRA or DSA and pBOS or BOS. The short follow-
up duration or the inclusion of pBOS could explain the
differences between our results and those of previous
studies.
This study had some limitations. First, this was a
retrospective cohort study, with a limited number of pa-
tients at a single center. Second, the follow-up duration
was relatively short; accordingly, long-term outcomes
are unclear. Third, single antigen assays were not per-
formed in all patients; therefore, some DSA could be
missed. Finally, we did not determine the proximal
mechanism underlying the observed link between high
PRA and outcome.
Despite these limitations, this study was the first to
evaluate the distribution of pre-lung transplantation
anti-HLA antibodies in Asia, where a relatively small
volume of lung transplants has been performed. Since
there is very little data reported on the status of pBOS
or BOS after lung transplantation in Asia, it may be
meaningful in spite of these limitations.
Considering the results of this study, patients with a
high MFI before lung transplantation should be consid-
ered for desensitization, close observation and careful
post-op management because high-grade PGD, which is
highly related to short-term mortality, was more com-
mon in patients with high MFI than in those with low
MFI in Asia.
Conclusions
The proportion of patients with high PRA and high MFI
were not high in lung transplant recipients in Korea, and
high MFI was related to high-grade PGD, but not to
pBOS or BOS. Caution is needed in the management of
sensitized patients and further prospective and long-
term studies are required.
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